Gluten in Medicine Act 2019

Link: The Gluten in Medicine Disclosure Act of 2019 Introduced in the House

An excerpt:

On April 3, 2019, Representatives Tim Ryan (D-OH) and Tom Cole (R-OK) introduced H.R. 2074, the Gluten in Medicine Disclosure Act of 2019. The bill intends to make it easier to identify gluten in prescription medications by requiring drug manufacturers to label medications with the list of ingredients, their source, and whether gluten is present.

The Celiac Disease Foundation has been working with Representative Ryan’s staff since 2012 on the need for labeling of gluten in medication and is proud to endorse this bill. The Gluten in Medicine Disclosure Act of 2019 was introduced in the House of Representatives and referred to the House Committee on Energy and Commerce. If passed by the House, the bill will move forward for review by the Senate.

Read the full text of the Gluten in Medicine Disclosure Act of 2019 here.

Take a minute to send our letter to your Members of Congress to urge them to cosponsor this bill.

Systematic Review of Gluten Introduction

A recent systematic review/meta-analysis (MI Pinto-Sanchez et al. J Pediatr 2016; 168: 132-43) identified 15 eligible studies among an initial search of 1982 studies.

Key findings:

  • There was a 25% increase in celiac disease risk with late (>6 months) vs recommended (4-6 months) gluten introduction.
  • There was no significant effect of breastfeeding or not breastfeeding.

The authors state there is no evidence on whether early introduction (<4 months) of gluten would affect the risk of celiac disease.  Late introduction (>6 months) is associated with increase risk of celiac disease.

Related blog posts:

Isla Verde, San Juan

Isla Verde, San Juan